21 related articles for article (PubMed ID: 9243304)
1. Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats.
Vyavahare N; Jones PL; Tallapragada S; Levy RJ
Am J Pathol; 2000 Sep; 157(3):885-93. PubMed ID: 10980128
[TBL] [Abstract][Full Text] [Related]
2. Extracts of Bauhinia championii (Benth.) Benth. attenuate the inflammatory response in a rat model of collagen-induced arthritis.
Xu W; Huang M; Zhang Y; Li H; Zheng H; Yu L; Chu K; Lin Y; Chen L
Mol Med Rep; 2016 May; 13(5):4167-74. PubMed ID: 27035125
[TBL] [Abstract][Full Text] [Related]
3. Control of death receptor ligand activity by posttranslational modifications.
Weinlich R; Brunner T; Amarante-Mendes GP
Cell Mol Life Sci; 2010 May; 67(10):1631-42. PubMed ID: 20306114
[TBL] [Abstract][Full Text] [Related]
4. Esculetin inhibits cartilage resorption induced by interleukin 1alpha in combination with oncostatin M.
Elliott S; Rowan AD; Carrère S; Koshy P; Catterall JB; Cawston TE
Ann Rheum Dis; 2001 Feb; 60(2):158-65. PubMed ID: 11156550
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.
Maskos K; Fernandez-Catalan C; Huber R; Bourenkov GP; Bartunik H; Ellestad GA; Reddy P; Wolfson MF; Rauch CT; Castner BJ; Davis R; Clarke HR; Petersen M; Fitzner JN; Cerretti DP; March CJ; Paxton RJ; Black RA; Bode W
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3408-12. PubMed ID: 9520379
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.
Leib SL; Clements JM; Lindberg RL; Heimgartner C; Loeffler JM; Pfister LA; Täuber MG; Leppert D
Brain; 2001 Sep; 124(Pt 9):1734-42. PubMed ID: 11522576
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.
Clements JM; Cossins JA; Wells GM; Corkill DJ; Helfrich K; Wood LM; Pigott R; Stabler G; Ward GA; Gearing AJ; Miller KM
J Neuroimmunol; 1997 Apr; 74(1-2):85-94. PubMed ID: 9119983
[TBL] [Abstract][Full Text] [Related]
8. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis.
Redford EJ; Smith KJ; Gregson NA; Davies M; Hughes P; Gearing AJ; Miller K; Hughes RA
Brain; 1997 Oct; 120 ( Pt 10)():1895-905. PubMed ID: 9365379
[TBL] [Abstract][Full Text] [Related]
9. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases.
Matyszak MK; Perry VH
J Neuroimmunol; 1996 Sep; 69(1-2):141-9. PubMed ID: 8823386
[TBL] [Abstract][Full Text] [Related]
10. Effect of a matrix metalloproteinase inhibitor (BB-1101) on nerve regeneration.
Demestre M; Gregson NA; Smith KJ; Miller KM; Gearing AJ; Hughes RA
Ann N Y Acad Sci; 1999 Jun; 878():658-61. PubMed ID: 10415800
[No Abstract] [Full Text] [Related]
11. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing.
DiMartino M; Wolff C; High W; Stroup G; Hoffman S; Laydon J; Lee JC; Bertolini D; Galloway WA; Crimmin MJ; Davis M; Davies S
Inflamm Res; 1997 Jun; 46(6):211-5. PubMed ID: 9243304
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing.
Yamamoto M; Hirayama R; Naruse K; Yoshino K; Shimada A; Inoue S; Kayagaki N; Yagita H; Okumura K; Ikeda S
Drug Des Discov; 1999 Aug; 16(2):119-30. PubMed ID: 10533808
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
